April 2026 Ligand Pharmaceuticals strengthened its dermatology collaborations by expanding support for cantharidin-based therapies targeting molluscum contagiosum through strategic licensing and development initiatives.
February 2026 Novan, Inc. advanced research efforts focused on nitric oxide-based topical therapies for viral skin conditions, including molluscum contagiosum, supporting innovation in non-invasive dermatological treatments.
September 2025 Verrica Pharmaceuticals expanded the commercial availability of YCANTH® through broader market access initiatives and healthcare provider engagement programs, improving patient access to FDA-approved treatment options for molluscum contagiosum.
May 2025 Bausch Health strengthened its dermatology portfolio by expanding topical treatment offerings and educational initiatives supporting the management of viral skin infections, including molluscum contagiosum.